{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:33:01Z","timestamp":1784698381338,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xkme.2025.101092","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T01:25:43Z","timestamp":1755653143000},"page":"101092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute Interstitial Nephritis Induced by Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)\u2014Unveiling a New Association: A Case Report"],"prefix":"10.1016","volume":"7","author":[{"given":"Maria J.","family":"Vargas-Brochero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poemlarp","family":"Mekraksakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind K.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.xkme.2025.101092_bib1","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","article-title":"Migraine: from pathophysiology to treatment","volume":"270","author":"Puledda","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101092_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/head.14234","article-title":"Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment","volume":"62","author":"Lainez","year":"2022","journal-title":"Headache"},{"issue":"12","key":"10.1016\/j.xkme.2025.101092_bib3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40263-023-01050-3","article-title":"Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine: a prospective multicenter cohort study","volume":"37","author":"Caponnetto","year":"2023","journal-title":"CNS Drugs"},{"issue":"22","key":"10.1016\/j.xkme.2025.101092_bib4","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2025.101092_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14728214.2023.2207819","article-title":"Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials","volume":"28","author":"Silvestro","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.xkme.2025.101092_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","article-title":"Mode and site of action of therapies targeting CGRP signaling","volume":"24","author":"Labastida-Ramirez","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.xkme.2025.101092_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40122-020-00159-3","article-title":"An evidence-based review of fremanezumab for the treatment of migraine","volume":"9","author":"Urits","year":"2020","journal-title":"Pain Ther"},{"issue":"3","key":"10.1016\/j.xkme.2025.101092_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231152169","article-title":"Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis","volume":"43","author":"Messina","year":"2023","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.xkme.2025.101092_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cod.14018","article-title":"First confirmed case of nonimmediate hypersensitivity to fremanezumab during chronic migraine treatment","volume":"86","author":"Moya","year":"2022","journal-title":"Contact Dermatitis"},{"issue":"8","key":"10.1016\/j.xkme.2025.101092_bib10","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jaip.2023.05.008","article-title":"Hypersensitivity to galcanezumab with tolerance to erenumab and fremanezumab","volume":"11","author":"Gonzalez-Cano","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.xkme.2025.101092_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280221118402","article-title":"Efficacy and safety of erenumab, galcanezumab, and fremanezumab in the treatment of drug-resistant chronic migraine: experience in real clinical practice","volume":"57","author":"Cantarelli","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.xkme.2025.101092_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0333102417747230","article-title":"Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging Phase 2b study","volume":"38","author":"Oakes","year":"2018","journal-title":"Cephalalgia"},{"issue":"18","key":"10.1016\/j.xkme.2025.101092_bib13","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.xkme.2025.101092_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.ackd.2016.11.016","article-title":"Medication-induced interstitial nephritis in the 21st century","volume":"24","author":"Nast","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2025.101092_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.ackd.2016.11.004","article-title":"Mechanisms of drug-induced interstitial nephritis","volume":"24","author":"Raghavan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2025.101092_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000525561","article-title":"Facing the challenge of drug-induced acute interstitial nephritis","volume":"147","author":"Sanchez-Alamo","year":"2023","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.xkme.2025.101092_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10194-020-01211-5","article-title":"Immunogenicity of biologic therapies for migraine: a review of current evidence","volume":"22","author":"Cohen","year":"2021","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.xkme.2025.101092_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1208\/s12248-024-00901-1","article-title":"Implications of immunogenicity testing for therapeutic monoclonal antibodies: a quantitative pharmacology framework","volume":"26","author":"Williams","year":"2024","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xkme.2025.101092_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.xkme.2025.101092_bib20","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ckj\/sfad109","article-title":"Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis","volume":"16","author":"Miao","year":"2023","journal-title":"Clin Kidney J"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:33:28Z","timestamp":1772915608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2590059525001281"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101092","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Interstitial Nephritis Induced by Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)\u2014Unveiling a New Association: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101092"}}